Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.

Cancer chemotherapy and pharmacology - 1 Jun 2012

Mueller Annett, Bachmann Erika, Linnig Monika, Khillimberger Katrin, Schimanski Carl Christoph, Galle Peter R, Moehler Markus

Abstract excerpt

PURPOSE: New targeted agents like antibodies or small molecules against tyrosine and lipid kinases clearly expand the standard therapy options in oncology. However, tumour resistance is still a challenge, often induced by mutations in growth-related signalling cascades. Twenty and ten percentage of all patients with colorectal and gastric cancers, respectively, carry phosphatidyl-3-kinase (PI3K) mutations and do...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle Checkpoints

Share to HCT116 Cells

Share to HT29 Cells

Share to Irinotecan

Share to Morpholines

Share to Phosphoinositide-3 Kinase Inhibitors

Source

Identifiers

PMID: 22543857
DOI: 10.1007/s00280-012-1869-z

Genes

DLD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.PMID 22543857Read ↗

Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.Semantic proximity Read ↗

Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA MutationsSemantic proximity Read ↗

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.Semantic proximity Read ↗

Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.Semantic proximity Read ↗

Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition.Semantic proximity Read ↗

PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.Semantic proximity Read ↗

Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.Semantic proximity Read ↗

From PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer.Semantic proximity Read ↗

Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1Semantic proximity Read ↗

Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.Semantic proximity Read ↗

PI3K/Akt and GSK-3β prevents in a differential fashion the malignant phenotype of colorectal cancer cells.Semantic proximity Read ↗

PI-3-Kinase inhibitors in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.